Aslan Debt Current vs Total Debt Analysis
ASLN Stock | USD 0.63 0.01 1.56% |
Trend analysis of Aslan Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 45.4 M, Other Current Liabilities of 1.8 M or Total Current Liabilities of 28 M provides information on Aslan Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Aslan Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Aslan Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Aslan |
About Aslan Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Aslan Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Aslan Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aslan Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aslan currently owns. An asset can also be divided into two categories, current and non-current.
Aslan Pharmaceuticals Balance Sheet Chart
Aslan Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Aslan Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Aslan Pharmaceuticals' Common Stock Shares Outstanding is very stable compared to the past year. As of the 28th of March 2024, Other Current Assets is likely to grow to about 4.8 M, while Total Assets are likely to drop about 47.1 M. Add Fundamental
Total Assets
Total assets refers to the total amount of Aslan Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aslan Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Aslan Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aslan Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Aslan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aslan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Aslan Stock, please use our How to Invest in Aslan Pharmaceuticals guide.As of the 28th of March 2024, Selling General Administrative is likely to drop to about 9.5 M. In addition to that, Tax Provision is likely to drop to about 141.5 K
Aslan Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Aslan Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aslan Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 23.3M | 16.1M | 94.5M | 61.2M | 70.4M | 47.1M | |
Short Long Term Debt Total | 18.4M | 19.3M | 31.1M | 37.6M | 43.3M | 45.4M | |
Other Current Liab | 3.2M | 267K | 223.4K | 2.4M | 2.8M | 1.8M | |
Total Current Liabilities | 5.4M | 10.7M | 6.4M | 23.2M | 26.6M | 28.0M | |
Total Stockholder Equity | (1.7M) | (10.5M) | 57.3M | 8.4M | 9.6M | 12.1M | |
Other Liab | 4.8M | 8.9M | 13.4M | 112.0K | 128.8K | 122.3K | |
Net Tangible Assets | (50.3M) | (10.5M) | 57.3M | 8.4M | 7.5M | 7.1M | |
Property Plant And Equipment Net | 766.2K | 475.9K | 232.7K | 292.7K | 336.7K | 375.0K | |
Net Debt | (3.8M) | 4.9M | (59.1M) | (19.3M) | (17.4M) | (18.2M) | |
Retained Earnings | (179.5M) | (195.7M) | (227.0M) | (278.4M) | (250.5M) | (238.0M) | |
Accounts Payable | 1.9M | 2.3M | 3.1M | 12.8M | 14.7M | 15.4M | |
Cash | 22.2M | 14.3M | 90.2M | 56.9M | 65.4M | 42.3M | |
Non Current Assets Total | 1.1M | 579.4K | 737.4K | 307.2K | 353.2K | 335.6K | |
Non Currrent Assets Other | 108.1K | 103.3K | 10.0K | 8.6M | 9.9M | 10.4M | |
Long Term Debt | 17.6M | 15.2M | 30.9M | 29.7M | 26.7M | 25.4M | |
Cash And Short Term Investments | 22.2M | 14.3M | 90.2M | 56.9M | 65.4M | 42.3M | |
Common Stock Total Equity | 43.8M | 51.6M | 61.4M | 61.8M | 71.1M | 40.0M | |
Common Stock Shares Outstanding | 6.5M | 7.7M | 13.0M | 13.9M | 16.0M | 16.8M | |
Liabilities And Stockholders Equity | 23.3M | 16.1M | 94.5M | 61.2M | 70.4M | 47.1M | |
Non Current Liabilities Total | 18.6M | 15.6M | 30.9M | 29.7M | 26.7M | 19.4M | |
Other Current Assets | 68.9K | 649.1K | 3.6M | 4.0M | 4.6M | 4.8M | |
Other Stockholder Equity | 116.5M | 123.6M | 221.5M | 223.9M | 257.5M | 270.4M | |
Total Liab | 24.0M | 26.2M | 37.2M | 52.8M | 60.7M | 34.8M | |
Property Plant And Equipment Gross | 766.2K | 475.9K | 232.7K | 292.7K | 336.7K | 375.0K | |
Total Current Assets | 22.3M | 15.5M | 93.8M | 60.9M | 70.0M | 43.6M | |
Short Term Debt | 264.5K | 3.8M | 199.1K | 8.0M | 7.2M | 3.7M | |
Intangible Assets | 23.1M | 2.8K | 160.0 | 5.8M | 6.7M | 4.8M | |
Common Stock | 51.6M | 61.4M | 61.8M | 63.0M | 72.5M | 46.5M | |
Property Plant Equipment | 23.0M | 475.9K | 232.7K | 292.7K | 263.5K | 250.3K | |
Capital Lease Obligations | 755.4K | 552.8K | 199.1K | 215.7K | 248.0K | 236.9K | |
Non Current Liabilities Other | 161.8K | 289.6K | 447.2K | 112.0K | 128.8K | 185.3K | |
Net Invested Capital | 16.0M | 8.2M | 88.2M | 45.8M | 52.6M | 45.4M | |
Net Working Capital | 16.9M | 4.8M | 87.4M | 37.7M | 43.4M | 39.0M |
Pair Trading with Aslan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Aslan Stock
0.5 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
0.42 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Aslan Stock, please use our How to Invest in Aslan Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Aslan Stock analysis
When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.00) | Revenue Per Share 0.769 | Return On Assets (0.47) | Return On Equity (4.27) |
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.